retatrutide obesity phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Another Promising Medication (Retatrutide) for

Losing muscle reduces your metabolic rate, making continued weight loss harder and increasing the likelihood of regain later

Ambulatory blood pressure monitoring showed that tirzepatide actually reduces both systolic and diastolic blood pressure, partially offsetting any heart rate increase from a cardiovascular risk perspective

Healthy Digestion & Gut Balance - A prebiotic ingredient promotes the growth of Akkermansia muciniphila, an intestinal bacterium associated with improved GLP-1 signalling

It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR

Gallbladder issues in people who lose weight rapidly

After 4 to 6 weeks, the dose can be increased to 1.0 mg if tolerated well